Precision BioSciences, Inc. (DTIL)Healthcare | Biotechnology | Durham, United States | NasdaqCM
6.10 USD
-0.43
(-6.585%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 6.10 |
Hot Take ↕ | Oct. 10, 2026, 4:14 a.m. EDT
This is a catastrophic long-term investment with a fleeting, high-risk speculative opportunity. The company has suffered a structural implosion, dropping nearly 97.5% over the last six years with four consecutive years of negative annual returns. Fundamentals are dire: the business is burning cash aggressively with negative operating margins, negative free cash flow, and a forward P/E that indicates no expected earnings. Despite a massive analyst price target of $60, this is likely a fantasy disconnected from the reality of a biotech firm with no revenue growth and a shrinking balance sheet. Short-term traders might see a bounce due to recent trial data headlines, but the options market tells a different story. Speculators are dumping calls and loading up on puts, betting on further decline rather than a recovery. The statistical forecast model offers no directional guidance, confirming the lack of a clear trend. Unless the upcoming trial results represent a paradigm-shifting breakthrough that instantly validates the entire pipeline, the odds favor continued deterioration. Avoid this as a long-term hold; it is a value trap where the low price reflects a broken business model. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.086630 |
| AutoETS | 0.086630 |
| MSTL | 0.090407 |
| AutoTheta | 0.120248 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 1.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.361 |
| Excess Kurtosis | -0.97 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 62.043 |
| Revenue per Share | 2.213 |
| Market Cap | 168,369,472 |
| Forward P/E | -3.28 |
| Beta | 1.28 |
| Profit Margins | -117.04% |
| Website | https://precisionbiosciences.com |
As of Oct. 10, 2026, 4:14 a.m. EDT: Speculators are overwhelmingly bearish, positioning heavy put volume against minimal call interest. In the near term (October/November 2026), put open interest significantly exceeds call open interest, with notable new flow into December puts. While there is some speculative call buying at $12.50 strikes for early 2027, the dominant sentiment is a bet on further downside, reinforced by the stark imbalance in volume and open interest across all expirations.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.11623931 |
| Address1 | 302 East Pettigrew St. |
| Address2 | Suite A-100 |
| All Time High | 710.1 |
| All Time Low | 3.53 |
| Ask | 6.12 |
| Ask Size | 1 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 233,580 |
| Average Daily Volume3 Month | 274,712 |
| Average Volume | 274,712 |
| Average Volume10Days | 233,580 |
| Beta | 1.275 |
| Bid | 4.56 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 1.713 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.1 |
| Current Ratio | 12.822 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 6.55 |
| Day Low | 6.05 |
| Debt To Equity | 62.043 |
| Display Name | Precision BioSciences |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,622,600 |
| Earnings Timestamp Start | 1,793,622,600 |
| Ebitda | -35,148,000 |
| Ebitda Margins | -0.78011 |
| Enterprise To Ebitda | -3.099 |
| Enterprise To Revenue | 2.418 |
| Enterprise Value | 108,921,480 |
| Eps Current Year | -3.86667 |
| Eps Forward | -1.86 |
| Eps Trailing Twelve Months | -1.35 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 480 393 5553 |
| Fifty Day Average | 7.1928 |
| Fifty Day Average Change | -1.0928001 |
| Fifty Day Average Change Percent | -0.15192972 |
| Fifty Two Week Change Percent | 11.623931 |
| Fifty Two Week High | 9.62 |
| Fifty Two Week High Change | -3.52 |
| Fifty Two Week High Change Percent | -0.36590436 |
| Fifty Two Week Low | 3.53 |
| Fifty Two Week Low Change | 2.57 |
| Fifty Two Week Low Change Percent | 0.7280453 |
| Fifty Two Week Range | 3.53 - 9.62 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,553,779,800,000 |
| Float Shares | 25,451,945 |
| Forward Eps | -1.86 |
| Forward P E | -3.2795699 |
| Free Cashflow | -16,252,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 67 |
| Fullday Change | -0.4300003 |
| Fullday Change Percent | -6.5849967 |
| Fullday Price | 6.1 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 45,055,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.080419995 |
| Held Percent Institutions | 0.68714 |
| Implied Shares Outstanding | 27,601,554 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,707,868,800 |
| Last Split Factor | 1:30 |
| Long Business Summary | Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. |
| Long Name | Precision BioSciences, Inc. |
| Market | us_market |
| Market Cap | 168,369,472 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_41018856 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -53,617,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 175,545,883 |
| Number Of Analyst Opinions | 5 |
| Open | 6.51 |
| Operating Cashflow | -51,899,000 |
| Operating Margins | -0.80779 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 919 314 5512 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.1 |
| Post Market Time | 1,791,921,711 |
| Previous Close | 6.53 |
| Price Eps Current Year | -1.5775849 |
| Price Hint | 2 |
| Price To Book | 3.561004 |
| Price To Sales Trailing12 Months | 3.7369764 |
| Profit Margins | -1.17039 |
| Quick Ratio | 12.262 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.43 |
| Regular Market Change Percent | -6.585 |
| Regular Market Day High | 6.55 |
| Regular Market Day Low | 6.05 |
| Regular Market Day Range | 6.05 - 6.55 |
| Regular Market Open | 6.51 |
| Regular Market Previous Close | 6.53 |
| Regular Market Price | 6.1 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 326,681 |
| Return On Assets | -0.19372 |
| Return On Equity | -1.35146 |
| Revenue Per Share | 2.213 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 27,601,554 |
| Shares Percent Shares Out | 0.0911 |
| Shares Short | 2,514,044 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,518,952 |
| Short Name | Precision BioSciences, Inc. |
| Short Percent Of Float | 0.0933 |
| Short Ratio | 9.96 |
| Source Interval | 15 |
| State | NC |
| Symbol | DTIL |
| Target High Price | 60.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 29.4 |
| Target Median Price | 20.0 |
| Total Cash | 87,549,000 |
| Total Cash Per Share | 3.172 |
| Total Debt | 28,101,000 |
| Total Revenue | 45,055,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.369575 |
| Two Hundred Day Average Change | -0.26957512 |
| Two Hundred Day Average Change Percent | -0.042322308 |
| Type Disp | Equity |
| Volume | 326,681 |
| Website | https://precisionbiosciences.com |
| Zip | 27,701 |